DRI Healthcare Reports Third Quarter 2025 Results
Subsequent to the end of the quarter, DRI Healthcare acquired a royalty interest in the U.S. net sales of veligrotug and VRDN-003, for up to $300 million Portfolio assets generated Total Income of $48.7 million Reactivated NCIB and repurchased ~394 K units for $4.1 million TORONTO, Nov. 5, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) […]
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug and VRDN-003 for the Treatment of Thyroid Eye Disease (TED)
–Third synthetic royalty transaction & second pre-approval deal for DRI –– Further increases portfolio exposure to rare diseases –– Long-dated cashflows, extend portfolio duration –– DRI Healthcare to pay US$55 million upfront; up to US$300 million total investment, subject to achievement of certain milestones– TORONTO, Oct. 20, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: […]
DRI Healthcare to Host Third Quarter 2025 Earnings Call and Webcast on November 6, 2025
TORONTO, Oct. 16, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”), a global leader in providing financing to advance innovation in the life sciences industry, announces that it will hold a conference call to discuss its third quarter 2025 financial results on Thursday, November 6, 2025, at 8:00 a.m. ET. DRI Healthcare […]
DRI Healthcare Trust Promotes Zaheed Mawani to Chief Financial Officer
TORONTO, Sept. 19, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare“) is pleased to announce the promotion of Zaheed Mawani to Chief Financial Officer, effective October 1, 2025. Mr. Mawani joined DRI Healthcare in October 2024 as Chief Compliance Officer and has been providing strategic leadership ensuring DRI Healthcare adheres to government […]
DRI Healthcare to Present at Upcoming Investor Conferences
TORONTO, Sept. 16, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”), a global leader in providing financing to advance innovation in the life sciences industry, today announced that it will present at the following investor conferences in September and October: 24th Annual CIBC Eastern Institutional Investor Conference Date: September 25, 2025Presentation […]
DRI Healthcare Reports Second Quarter 2025 Results
Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management function Portfolio assets generate Total Income of $44.1 million Reactivated NCIB and repurchased ~958 K units for $9.1 million, while redeeming $10 million of Series C Preferred Securities for $9.5 million TORONTO, Aug. 13, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI […]
DRI Healthcare to Host Second Quarter 2025 Earnings Call and Webcast on August 14, 2025
TORONTO, July 24, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”), a global leader in providing financing to advance innovation in the life sciences industry, today announced that it will hold a conference call to discuss its second quarter 2025 financial results on Thursday, August 14, 2025, at 8:00 a.m. ET. The […]
DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals’ Ekterly® (sebetralstat)
– Ekterly is the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema – – DRI Healthcare is entitled to a tiered royalty on worldwide net sales of Ekterly – – KalVista has elected to receive additional funding increasing our total investment to $127 million – TORONTO, July 8, 2025 /CNW/ […]
DRI Healthcare Announces Closing of Internalization Transaction
TORONTO, July 1, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”) today announced that it has completed its previously announced transaction to internalize its investment management function. “We are excited to complete this transaction and begin our next chapter as one integrated organization,” said Gary Collins, Executive Chair of DRI Healthcare. […]
DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints
– FDA decision anticipated within four weeks – TORONTO, June 13, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the “Trust”) today announced KalVista Pharmaceuticals (“KalVista”) has disclosed that it has received notice from the U.S. Food and Drug Administration (“FDA”) that the FDA will not meet the June 17, 2025 PDUFA goal date for […]